Please login to the form below

Not currently logged in
Email:
Password:

GSK Biologicals signs Alzheimer's deal with AFFiRiS

GlaxoSmithKline's (GSK) vaccine division has acquired exclusive rights to develop and commercialise two Alzheimer's vaccine candidates

GlaxoSmithKline's (GSK) vaccine division has acquired exclusive rights to develop and commercialise two Alzheimer's vaccine candidates.

The vaccines, which are currently under Phase I clinical development, are being developed using the AFFiRiS' AFFiTOPE technology. This allows the development of proteins that bind to the disease-causing human proteins that are central to the pathology of Alzheimer's disease.

Jean Stephenne, president and general manager of GlaxoSmithKline Biologicals said: "We are impressed with the AFFiRiS technology - combined with our expertise in innovative adjuvant systems this collaboration will improve our chance of success in the discovery of new treatments against this major disease."

The deal will see AFFiRIS receive an up-front payment of £17.5m with the possibility of future milestone and royalty payments. In the event of the vaccines reaching full commercial success and gaining government authority approval, the value of the agreement could reach £334m.

23rd October 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PRMA Consulting Ltd

PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...

Latest intelligence

What are you doing, Dave?
Artificial Intelligence (AI) is invading all areas of healthcare. Is it our saviour or our nemesis?...
Fake News is Bad for your Health
Ill informed patients make poor health decisions...
Secrets of Pharma Advertising
If the goal of branding is to be different, why do so many Pharma brand ads look the same?...

Infographics